• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Ocular Therapeutix

Ocular Therapeutix adds two executives to leadership team

June 8, 2022 By Sean Whooley

Ocular Therapeutix (Nasdaq:OCUL) announced today that it made two additions to its executive leadership team. Bedford, Massachusetts-based Ocular Therapeutix appointed a chief medical advisor (CMA) — a newly created role — as well as a new chief medical officer (CMO). Additionally, the company created a new role called chief strategy advisor (CSA) for its departing […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, Optical/Ophthalmic Tagged With: Ocular Therapeutix, Personnel Moves

Ocular Therapeutix posts mixed-bag Q1 results

May 10, 2022 By Danielle Kirsh

Ocular Therapeutix (NSDQ:OCUL) this week posted first-quarter results that beat the earnings consensus on Wall Street but missed revenue estimates. The Bedford, Massachusetts-based company reported losses of $12.5 million, or -16¢ per share, on sales of $13.2 million for the three months ended March 31, for sales growth of 79.6% compared with Q1 2021. Earnings […]

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

Ocular Therapeutix misses on Q4 projections

March 1, 2022 By Sean Whooley

Ocular Therapeutix (NSDQ:OCUL) shares ticked up today despite fourth-quarter results that missed the consensus revenue forecast. The Bedford, Massachusetts-based company posted losses of $3.9 million, or 5¢ per share, on sales of $12.3 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain moving from $85.6 million in losses this time […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

Ocular Therapeutix touts positive trial results of ophthalmic insert for dry eye disease

December 6, 2021 By Sean Whooley

Ocular Therapeutix (NSDQ:OCUL) announced today that it reported positive results from a Phase 2 trial of its dry eye disease treatment. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based Phase 2 clinical trial evaluated OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Optical/Ophthalmic Tagged With: Ocular Therapeutix

Ocular Therapeutix claims win as court invalidates drug delivery patent from Mati

November 9, 2021 By Sean Whooley

Ocular Therapeutix (NSDQ:OCUL) announced today that an appeals court invalidated a drug delivery system patent held by Mati Therapeutics. The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., invalidated the patent related to a drug delivery system containing dexamethasone, affirming the judgment made in June 2020 by the Patent Trial and Appeal Board […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, Legal News, Optical/Ophthalmic, Patent Infringement, Regulatory/Compliance Tagged With: Ocular Therapeutix

Ocular Therapeutix dry eye treatment trial fails to meet primary endpoint

October 22, 2021 By Sean Whooley

Ocular Therapeutix (NSDQ:OCUL) announced today that its Phase 2 clinical trial for treating dry eye disease (DED) did not meet its primary endpoint. Bedford, Massachusetts-based Ocular Therapeutix’s U.S.-based, randomized, double-masked, multi-center, vehicle-controlled Phase 2 clinical trial evaluated OTX-CSI (cyclosporine intracanalicular insert) for treating DED by measuring signs and symptoms of DED in 140 subjects treated in […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Ocular Therapeutix

Ocular Therapeutix misses on earnings, tops Q2 revenue estimates

August 10, 2021 By Sean Whooley

Ocular Therapeutix (NSDQ:OCUL) shares ticked up this morning on second-quarter results that topped revenue forecasts. OCUL shares were up nearly 2% at $10.94 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly. Get the full story at our sister site, Drug Delivery Business […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

Ocular Therapeutix misses The Street on bottom-line leap

May 6, 2021 By Nancy Crotti

Ocular Therapeutix (NSDQ:OCUL) reported first-quarter results that missed the consensus forecast on Wall Street. The Bedford, Mass.–based eye disease therapeutic developer posted profits of $3.12 million, or $0.04 per share, on sales of $7.34 million for the three months ended March 31, 2021, for a bottom-line leap of 114% on sales growth of 181% compared […]

Filed Under: Business/Financial News, Drug-Device Combinations, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

Ocular Therapeutix reports Q4 misses

March 12, 2021 By Sean Whooley

Ocular Therapeutix (NSDQ:OCUL) reported fourth-quarter results that missed the consensus forecast. The Bedford, Mass.–based eye disease therapeutic developer posted losses of –$85.6 million, or –$1.21 per share, on sales of $7.3 million for the three months ended Dec. 31, 2020, for a massive bottom-line slide from losses of –$26 million last year despite more than […]

Filed Under: Business/Financial News, Drug-Device Combinations, Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: Ocular Therapeutix

Ocular Therapeutix commences public offering

May 20, 2020 By Sean Whooley

Ocular Therapeutix (NSDQ:OCUL) announced that it commenced an underwritten public offering of an undisclosed amount of its common stock. The Bedford, Mass.-based eye condition therapy developer filed with the SEC to confirm the offering with the shares at a par value of $0.0001 per share. The common stock at market close on May 18 prior to […]

Filed Under: Business/Financial News, Funding Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Ocular Therapeutix

Ocular Therapeutix posts wider-than-forecast Q1 results

May 8, 2020 By Danielle Kirsh

Ocular Therapeutix (NSDQ:OCUL) posted first-quarter results that beat the revenue consensus on Wall Street but missed on earnings. The company reported losses of -$21.5 million, or -41¢ per share, on sales of $2.6 million for the three months ended March 31, for a sales growth of 430.3% compared with Q1 2019. Earnings per share were -41¢, […]

Filed Under: Wall Street Beat Tagged With: Ocular Therapeutix

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS